학술논문
A qualitative research study in Japan investigating patients' experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment.
Document Type
Academic Journal
Author
Akakura K; Department of Urology, Japan Community Health Care Organization (JCHO) Tokyo Shinjuku Medical Center, 5-1 Tsukudo-cho, Shinjuku, 162-8543, Japan.; Uemura H; Department of Urology and Renal Transplantation, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.; Miyazaki K; School of Public Health, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan.; Stroupe A; Patient-Centered Outcomes, Open Health, Newton, MA 02458, USA.; Seo C; Patient-Centered Outcomes, Open Health, Bethesda, MD 20814, USA.; Uzumcu A; Patient-Centered Outcomes, Open Health, Newton, MA 02458, USA.; Ledesma DA; Market Access Oncology, Bayer Yakuhin, Ltd, Marunouchi 1-6-5, Chiyoda-ku, Tokyo, 100-8265, Japan.
Source
Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE
Subject
Language
English
Abstract
Aim: This qualitative study aimed to reveal symptoms and impacts among bone metastatic castration-resistant prostate cancer (or mCRPC) Japanese patients, prior to Radium-223 (Ra-223) treatment. Materials & Methods: Twenty-three mCRPC patients designated to receive Ra-223 and three treating physicians (Ra-223 prescribers) in Japan, were interviewed. All interview data were assessed for concept frequency, themes and saturation. Results: Forty-five percent of the patients (mean age: 75.8 years) were symptomatic at the time of enrollment. Interviews with all patients revealed 47 mCRPC symptoms, including back pain and bone-specific pain, and 45 life impacts, including worry about disease progression and the impact on daily, physical activities. Conclusion: The symptoms and impacts of living with mCRPC and the associated burden of bone metastasis and skeletal-related symptoms are varied and are important considerations for treatment.